N-(2-methoxyethyl)octylamine | 120530-31-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-methoxyethyl)octylamine
• 英文别名: N-(2-methoxyethyl)octan-1-amine
• CAS: 120530-31-6
• 化学式: C₁₁H₂₅NO
• mdl: MFCD03551896
• 分子量: 187.326
• InChiKey: DLSIXUMZNNBNFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  辛胺 、 乙二醇甲醚 在 chloro(η⁵-pentamethylcyclopentadienyl)(L-prolinato)iridium(III) 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以72%的产率得到N-(2-methoxyethyl)octylamine
  参考文献：
  名称：

  Selective Alkylation of Amines with Alcohols by Cp*–Iridium(III) Half-Sandwich Complexes

  摘要：

  [(CpIr)-Ir-star(Pro)Cl] (Pro = prolinato) was identified among a series of Cp-star-iridium half-sandwich complexes as a highly reactive and selective catalyst for the alkylation of amines with alcohols. It is active under mild conditions in either toluene or water without the need for base or other additives, tolerates a wide range of alcohols and amines, and gives secondary amines in good to excellent isolated yields.

  DOI：

  10.1021/ol303075h

文献信息

• Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10253018B2

  公开（公告）日：2019-04-09

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明公开了式 (I) 化合物或其药学上可接受的盐、酯、立体异构体、同分异构体、溶液剂、水合物或其组合： 其抑制与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾病、心血管疾病相关的凋亡信号调节激酶 1 (ASK-1)。本发明进一步涉及包含上述化合物的药物组合物，用于给患有 ASK-1 相关疾病的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 ASK-1 相关疾病的方法。本发明特别涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）。
• NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170305924A1

  公开（公告）日：2017-10-26

  The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.
• US9944654B2
  申请人：——

  公开号：US9944654B2

  公开（公告）日：2018-04-17
• Selective Alkylation of Amines with Alcohols by Cp*–Iridium(III) Half-Sandwich Complexes
  作者：Alexander Wetzel、Simone Wöckel、Mathias Schelwies、Marion K. Brinks、Frank Rominger、Peter Hofmann、Michael Limbach

  DOI：10.1021/ol303075h

  日期：2013.1.18

  [(CpIr)-Ir-star(Pro)Cl] (Pro = prolinato) was identified among a series of Cp-star-iridium half-sandwich complexes as a highly reactive and selective catalyst for the alkylation of amines with alcohols. It is active under mild conditions in either toluene or water without the need for base or other additives, tolerates a wide range of alcohols and amines, and gives secondary amines in good to excellent isolated yields.